CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Melatonin +1 moredrug
Likely dose
Melatonin 2.5 mg orally once daily for 3–4 weeksAI-extracted
Key inclusion· 2
  • ✓Diagnosed with uncomplicated hypertension
  • ✓Currently being treated with Atenolol (a beta-blocker)
Key exclusion· 5
  • ✕History of medical illness other than essential hypertension
  • ✕Personal or family history of psychiatric illness
  • ✕Current use of any medication other than anti-hypertensive drugs
  • ✕Any recent travel across time zones

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00238108
NCT00238108Phase 2Completed
CompareCT.gov

Melatonin Supplementation in Hypertensive Patients

Brigham and Women's Hospital·interventional·Posted Oct 13, 2005·Updated Nov 14, 2017

In Brief

A Phase 2 clinical trial evaluating Melatonin and Placebo for Sleep Disorders and Hypertension. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This study will evaluate the effectiveness of treatment with melatonin supplements in improving sleep in individuals with high blood pressure who are taking beta-blockers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSleep Disorders, Hypertension
CountriesUnited States
CollaboratorsNational Center for Complementary and Integrative Health (NCCIH), Office of Dietary Supplements (ODS)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 13, 2005
Enrollment StartOct 1, 2005
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 20.7 years ago

Interventions

Melatonindrug

2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks

Placebodrug

Placebo